Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (SKBHF)

Overview

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., established in 2016, is a pioneering biopharmaceutical entity focused on the innovation, manufacture, and global distribution of novel therapeutic solutions aimed at fulfilling the unresolved medical requirements within the People's Republic of China and beyond. Operating under the parent company Sichuan Kelun Pharmaceutical Co., Ltd., and headquartered in Chengdu, the company has established strategic partnerships with notable industry players such as Merck Sharp & Dohme LLC, Harbour BioMed Therapeutics Limited, and Ellipses Pharma Limited to fortify its research and development endeavors. Its primary mission revolves around providing advanced therapeutic options across various disease spectra, specifically in oncology and immunological disorders.

Products and Services

The product pipeline of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. encompasses a broad range of drug candidates under development, each tailored to combat a specific array of diseases, particularly focusing on cancerous and non-oncology ailments. The compounds exhibit a promising therapeutic potential, underpinned by innovative biotechnology research and collaborative efforts.

• SKB264 (sacituzumab tirumotecan): A novel oncology drug candidate engineered for the treatment of breast and non-small cell lung cancers, leveraging targeted therapy to combat tumor cells while sparing healthy tissues.
• A166 (trastuzumab botidotin): Specifically designed to target HER2-positive breast cancers, this antibody-drug conjugate aims at delivering potent cytotoxic agents directly to cancerous cells, thereby enhancing treatment efficacy and reducing systemic toxicity.
• SKB315, A167 (tagitanlimab), A140, and A400: Represent a suite of developmental drug candidates, each with unique mechanisms of action, intended to expand the therapeutics arsenal against various forms of cancer including gastrointestinal malignancies.
• A223, A277, SKB378, and SKB336: Focus on addressing immune-mediated conditions such as rheumatoid arthritis and alopecia areata. These non-oncology drug candidates emphasize Sichuan Kelun-Biotech’s commitment to improving life quality beyond cancer, by tackling a range of autoimmune diseases with cutting-edge biopharmaceutical solutions.